Expert Interview
Discussing BridgeBio/QED Therapeutics’ Oral Infigratinib Therapy for Children with Achondroplasia Ahead of the Phase 3 PROPEL 3 Readout
Ticker(s): BBIOInstitution: University of Sheffield
- Senior Clinical Lecturer in Musculoskeletal Genetics at University of Sheffield & Honorary Consultant Clinical Geneticist; Sheffield Children’s NHS Foundation Trust.
- Manages 5+ patients with achondroplasia.
- Lead Consultant Bone Geneticist for the nationally-commissioned Osteogenesis Imperfecta service in England.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
